Literature DB >> 307398

Prolymphocytic leukaemia of T-cell type: immunological, enzymatic and ultrastructural morphometric characteristics.

S Woessner, R Lafuente, J Sans-Sabrafen, J Vives, C Rozman.   

Abstract

A case of prolymphocytic leukaemia with immunological characteristics of T-cell type is reported. Three noteworthy findings can be emphasized: the presence of C3 receptors on the T-prolymphocytes, the study of the acid-phosphatase isoenzymatic pattern, which showed an increased band 3 with absence of band 3b, and the morphometric ultrastructural investigation. Cytochemistry and ultrastructural morphometry may be useful for a more precise characterization of prolymphocytic leukaemia and help to distinguish it from other lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 307398     DOI: 10.1111/j.1365-2141.1978.tb07122.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Nuclear alterations during lymphocyte transformation: relationship to the heterogeneous morphologic presentations of non-Hodgkin's lymphomas.

Authors:  I Dardick; G Setterfield; R Hall; T Bladon; J Little; G Kaplan
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

2.  B-lineage prolymphocytic leukemia as a distinct clinicopathologic entity.

Authors:  I Katayama; M Aiba; L Pechet; J L Sullivan; P Roberts; R E Humphreys
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

3.  T cells in patients with chronic T gamma lymphocytosis: morphology, cytochemistry, ultrastructure and immunological characteristics.

Authors:  J W Smit; N R Blom; M J van Luyn; F Miedema; C J Melief; M R Halie
Journal:  Blut       Date:  1985-08

4.  Single-cell screening of multiple biophysical properties in leukemia diagnosis from peripheral blood by pure light scattering.

Authors:  David Dannhauser; Domenico Rossi; Mimmo Ripaldi; Paolo A Netti; Filippo Causa
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.